April 6th 2024
New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
Most US Adults Fail to Recognize Heart Disease as Leading Killer of Americans, Study Finds
January 24th 2024The American Heart Association's annual report on heart disease and stroke statistics for 2024 sheds new light on the impact and level of public education surrounding the impact of heart disease and stroke in the US and abroad.
CLEAR Outcomes Analysis Finds Bempedoic Acid Reduces Total Cardiovascular Events by 20%
January 18th 2024In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.
Cardiology Month in Review: December 2023
January 3rd 2024Our cardiology month in review spotlights our most popular cardiology-centric content from the month of December 2023. The list includes topline data from SEQUOIA-HCM, new data on the impact of structural racism on chronic health conditions, and more!
Addressing Inflammation and Role of Colchicine in ASCVD, with Michael J. Blaha, MD, MPH
August 10th 2023Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.